Johnson & Johnson (NYSE:JNJ) Shares Acquired by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 48.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,773 shares of the company’s stock after purchasing an additional 4,810 shares during the period. Johnson & Johnson makes up 0.8% of Raleigh Capital Management Inc.’s holdings, making the stock its 26th biggest holding. Raleigh Capital Management Inc.’s holdings in Johnson & Johnson were worth $2,136,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Asset Planning Services Inc. LA ADV raised its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. Asset Planning Services Inc. LA ADV now owns 37,224 shares of the company’s stock valued at $5,383,000 after purchasing an additional 1,120 shares in the last quarter. True North Advisors LLC grew its holdings in shares of Johnson & Johnson by 2.9% during the fourth quarter. True North Advisors LLC now owns 9,046 shares of the company’s stock worth $1,308,000 after purchasing an additional 253 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Johnson & Johnson by 10.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 1,292,787 shares of the company’s stock worth $186,963,000 after buying an additional 120,815 shares during the period. Sharp Financial Services LLC raised its position in Johnson & Johnson by 14.9% in the 4th quarter. Sharp Financial Services LLC now owns 3,257 shares of the company’s stock valued at $471,000 after purchasing an additional 422 shares during the last quarter. Finally, Kelleher Financial Advisors lifted its position in Johnson & Johnson by 2.6% during the 4th quarter. Kelleher Financial Advisors now owns 6,516 shares of the company’s stock worth $942,000 after acquiring an additional 165 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on JNJ shares. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday. Wells Fargo & Company lowered their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday. Finally, Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Trading Up 0.1 %

Shares of NYSE:JNJ opened at $146.76 on Friday. The company has a 50 day moving average of $147.85 and a 200-day moving average of $155.99. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market cap of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.